


PSI-697

Cat. No.:	HY-15526		
CAS No.:	851546-61-7		
Molecular Formula:	C ₂₁ H ₁₈ ClNO ₃		
Molecular Weight:	367.83		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



Solvent & Solubility

In Vitro

DMSO : ≥ 45.8 mg/mL (124.51 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
	Concentration				
	1 mM		2.7186 mL	13.5932 mL	27.1865 mL
	5 mM		0.5437 mL	2.7186 mL	5.4373 mL
	10 mM		0.2719 mL	1.3593 mL	2.7186 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PSI-697 is a P-selectin inhibitor. In vivo: 30 mg/kg; oral gavage daily. Animals treated with PSI-697 show a significantly decreased intimal thickness score when compared with vehicle control IVCs. PSI-697 significantly decreased vein wall levels of platelet-derived growth factor. PSI-697 inhibits vein wall injury independently of thrombus mass. P-selectin inhibition seemed superior to LMWH in measured parameters of injury and mediator inhibition. PSI-697 inhibits vein wall injury independently of thrombus size in a rodent model of DVT. [1] PSI-697 (50 mg/kg p.o.) significantly reduced the number of rolling leukocytes by 39% (P < 0.05) versus vehicle control. In a rat venous thrombosis model, PSI-697 (100 mg/kg p.o.) reduced thrombus weight by 18% (P < 0.05) relative to vehicle, without prolonging bleeding time. [2] Animals receiving PSI-697 demonstrated significantly increased plasma D-dimer levels versus LMWH and control animals six hours post thrombus induction. [3]

REFERENCES

[1]. Myers DD Jr et al. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg. 2006 Sep;44(3):625-32.

[2]. Bedard PW et al. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther.

[3]. Myers DD Jr et al. Resolution of venous thrombosis using a novel oral small-molecule inhibitor of P-selectin (PSI-697) without anticoagulation. Thromb Haemost. 2007 Mar;97(3):400-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA